Author: Xudan Chen; Yang Zhang; Baoyi Zhu; Jianwen Zeng; Wenxin Hong; Xi He; Jingfeng Chen; Haipeng Zheng; Shuang Qiu; Ying Deng; Juliana Chan; Jian Wang
Title: Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study Document date: 2020_4_14
ID: 9j4ese89_29
Snippet: Lopinavir/ritonavir is a fixed dose combination of anti-HIV protease inhibitors acting against the viral 3CL protease [21] . Although it has been used to treat COVID-19 [22], its benefits has not been confirmed in a clinical trial involving COVID-19 patients with pneumonia in Wuhan [16] . In our study, apart from lack of benefit, the use of lopinavir/ ritonavir tended to delay viral RNA clearance, even after adjusting for factors including diseas.....
Document: Lopinavir/ritonavir is a fixed dose combination of anti-HIV protease inhibitors acting against the viral 3CL protease [21] . Although it has been used to treat COVID-19 [22], its benefits has not been confirmed in a clinical trial involving COVID-19 patients with pneumonia in Wuhan [16] . In our study, apart from lack of benefit, the use of lopinavir/ ritonavir tended to delay viral RNA clearance, even after adjusting for factors including disease severity.
Search related documents:
Co phrase search for related documents- benefit lack and disease severity: 1, 2, 3
- clinical trial and disease severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- clinical trial and dose combination: 1, 2, 3, 4, 5, 6, 7
- clinical trial and pneumonia patient: 1, 2, 3, 4, 5
- clinical trial and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- clinical trial and RNA clearance: 1, 2, 3, 4
- clinical trial and viral RNA clearance: 1, 2
- disease severity and dose combination: 1, 2
- disease severity and pneumonia patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- disease severity and protease inhibitor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- disease severity and RNA clearance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- disease severity and viral RNA clearance: 1, 2, 3, 4, 5, 6, 7, 8, 9
- disease severity and viral RNA clearance delay: 1, 2
- dose combination and protease inhibitor: 1, 2, 3, 4, 5
- pneumonia patient and Wuhan pneumonia patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- RNA clearance and viral RNA clearance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47
- RNA clearance and viral RNA clearance delay: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date